Which pricing strategy is most commonly used for orphan drugs that treat rare diseases affecting fewer than 200,000 patients in the US?

Orphan drugs treat rare diseases affecting small patient populations. Despite their life-saving potential, they present unique pricing challenges in the pharmaceutical industry. This poll explores the fascinating economics behind these specialized medications and tests your knowledge of pharmaceutical pricing strategies in this niche but crucial market segment.

This is a live public trivia poll on AIPolls.Net. Vote and see real-time results.

Premium pricing with annual costs often exceeding $100,000 per patient due to small patient populations and high R&D costs
Penetration pricing with deliberately low initial costs to capture market share before gradually increasing prices
Value-based pricing tied directly to measurable quality-adjusted life years (QALYs) with standardized caps
Cost-plus pricing where manufacturers charge only 15-20% above production costs due to regulatory mandates